User profiles for Andreia C de Melo
Andréia Cristina MeloINCA Verified email at inca.gov.br Cited by 3071 |
Sars-CoV-2/Covid-19 em pacientes com câncer
LCS Thuler, AC de Melo - Revista brasileira de cancerologia, 2020 - rbc.inca.gov.br
Em 12 de dezembro de 2019, um conjunto de casos de pneumonia causada por um coronavírus
recém-identificado foi anunciado em Wuhan, China. Esse coronavírus foi inicialmente …
recém-identificado foi anunciado em Wuhan, China. Esse coronavírus foi inicialmente …
Linfoma não-Hodgkin de alto grau-Revisão da literatura
…, APO de Souza Victorino, AC de Melo… - Revista brasileira de …, 2008 - rbc.inca.gov.br
Linfomas são transformações neoplásicas de células linfóides normais que residem
predominantemente em tecidos linfóides. O linfoma não-Hodgkin (LNH) é a quarta neoplasia mais …
predominantemente em tecidos linfóides. O linfoma não-Hodgkin (LNH) é a quarta neoplasia mais …
Determinants of COVID-19 mortality in patients with cancer from a community oncology practice in Brazil
PURPOSE The COVID-19 pandemic remains a public health emergency of global concern.
Determinants of mortality in the general population are now clear, but specific data on …
Determinants of mortality in the general population are now clear, but specific data on …
Triple negative breast cancer: A thorough review of biomarkers
…, P Izetti, GG de Mesquita, AC de Melo - Critical reviews in …, 2020 - Elsevier
Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of
expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 protein. The …
expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 protein. The …
[HTML][HTML] Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide
A Braga, P Mora, AC de Melo… - World journal of …, 2019 - ncbi.nlm.nih.gov
Gestational trophoblastic neoplasia (GTN) is a rare tumor that originates from pregnancy
that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and …
that includes invasive mole, choriocarcinoma (CCA), placental site trophoblastic tumor and …
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international …
…, A Fedenko, M Dvorkin, AC de Melo… - The Lancet …, 2022 - thelancet.com
Background Few prospective studies have compared poly(adenosine diphosphate-ribose)
polymerase (PARP) inhibitors to chemotherapy for the treatment of BRCA1-mutated or …
polymerase (PARP) inhibitors to chemotherapy for the treatment of BRCA1-mutated or …
[HTML][HTML] A review of mTOR pathway inhibitors in gynecologic cancer
AC de Melo, E Paulino, ÁHI Garces - Oxidative Medicine and …, 2017 - hindawi.com
The treatment of advanced gynecologic cancers remains palliative in most of cases. Although
systemic treatment has entered into the era of targeted drugs the antitumor efficacies of …
systemic treatment has entered into the era of targeted drugs the antitumor efficacies of …
[HTML][HTML] Survival with cemiplimab in recurrent cervical cancer
Background Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the
fully human programmed cell death 1 (PD-1)–blocking antibody approved to treat lung and …
fully human programmed cell death 1 (PD-1)–blocking antibody approved to treat lung and …
[HTML][HTML] Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer …
…, K Pennington, Z Novak, AC De Melo… - Journal of Clinical …, 2024 - ncbi.nlm.nih.gov
PURPOSE Immunotherapy and chemotherapy combinations have shown activity in endometrial
cancer, with greater benefit in mismatch repair (MMR)–deficient (dMMR) than MMR-…
cancer, with greater benefit in mismatch repair (MMR)–deficient (dMMR) than MMR-…
Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data
Background Cancer patients suffer from worse coronavirus disease-2019 (COVID-19)
outcomes. Whether active oncologic treatment is an additional risk factor in this population …
outcomes. Whether active oncologic treatment is an additional risk factor in this population …